Voyager Therapeutics IncVYGR
Price$2.68Intrinsic value$4.3763% above price

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $34.5M-56.9% YoYTTM through 30 Jun 2026
Net Income -$107.7MTTM through 30 Jun 2026
Free Cash Flow -$121.4MTTM through 30 Jun 2026

Margins

Current
Gross Margin64.1%
EBITDA Margin-328.0%
Operating Margin-1,167.6%
Net Margin-312.6%

Returns

-16.1%ROE
-12.7%ROA

Balance Sheet Health

Debt / Equity0.20x
Current Ratio3.79x
Net Debt-$137.1Mnet cash position
Cash & Equivalents$35.8M

Quality Metrics

Altman Z-Score-1.97
Piotroski F-Score0 / 9
FCF Margin-352.4%
Rule of 40-338.4
Earnings-Beat Rate75.0%

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $40.4M
Diluted EPS-$1.81TTM
'19'20'21'22'23'24'25
FY2025: $-2.04

Dividend

No dividend

Capital Allocation

Capex Intensity2.5%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.